New cancer drug begins first human safety tests
NCT ID NCT06607939
Summary
This early-stage study is testing a new drug called ORB-021 in people with advanced solid tumors that haven't responded to standard treatments. The main goal is to check if the drug is safe and to find the best dose for future studies. Researchers will give the drug through an IV and monitor patients closely for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Clinical Research
RECRUITINGScottsdale, Arizona, 85258, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MDAC
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.